IU physician researcher testing novel surgical technique for uterine, cervical cancer patients
Emma Rossi, M.D., assistant professor of obstetrics and gynecology at the IU School of Medicine and a physician researcher at the Indiana University Melvin and Bren Simon Cancer Center, was the first to describe a novel technique for sentinel lymph node mapping in uterine and cervical cancer patients.
Sentinel lymph node mapping uses an injected dye to identify the path of cancer cells in the lymph system. If cancer spreads from the primary tumor, it travels through the lymph system, and the first lymph node it reaches is known as the sentinel lymph node. If the cancer cells do not appear in the sentinel node, physicians know the malignant, or cancerous, cells have not traveled outside the primary tumor to spread through the lymph system.
Dr. Rossi is testing a novel technique for sentinel node mapping in a study comparing the detection of metastatic disease to routine lymphadenectomy, a more invasive surgical procedure in which the lymph nodes are removed and a sample of tissue is checked under a microscope for signs of cancer.
The fluorescing dye indocyanine green, or ICG, is injected into study participants in the cervix or endometrium before their cancer staging surgery. Dr. Rossi then uses an endoscope -- a thin, tube-like instrument used to look at tissues inside the body -- and a robotic camera that is capable of detecting the dye. The dye clearly identifies the nodes that receive drainage of cancer cells from the tumor.
“By using this technique, we only have to remove the sentinel nodes. Therefore, there is less cutting and potentially fewer complications,” said Dr. Rossi, who is the principal investigator for the IU study. “And we hope this technique will lead to an increased detection of cancer and save lives.”
The IU Simon Cancer Center is one of three sites where the study is being conducted. The others are the University of North Carolina at Chapel Hill and Summerlin Hospital Medical Center, Las Vegas. Dr. Rossi said the sites will enroll 1,000 patients over the next two to three years.
To learn more about this study, contact research coordinator Melissa Ade at 317-944-7026 or email@example.com.